Mike Schopperle received a Ph.D. in Biochemistry from Brandeis University and followed with postdoctoral studies in cancer research at Beth Israel Deaconess Medical Center, and an Instructor faculty position at Harvard Medical School to continue cancer stem cell research. In 2011 he co-founded CureMeta, a? biotech which focuses on novel therapeutics for aggressive and metastatic cancers. CureMeta develops therapeutic antibodies to novel cancer targets and over past 7 years has had remarkable success.? CureMeta is currently focused on taking it's lead therapeutic drug, Bstrongximab, into human clinical trials for patients with metastatic prostate and pancreatic cancers and recurring lymphomas.